Burzynski Research Institute, Inc. (BZYR)
USD 0.05
(-1.63%)
USD 0.05
(-1.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -1310.00 USD | -40.26% |
| 2023 | -934.00 USD | 72.38% |
| 2022 | -3382.00 USD | -5354.84% |
| 2021 | -62.00 USD | 61.96% |
| 2020 | -163.00 USD | 76.98% |
| 2019 | -708.00 USD | -39.92% |
| 2018 | -506.00 USD | 30.78% |
| 2017 | -731.00 USD | 77.87% |
| 2016 | -3303.00 USD | -44.87% |
| 2015 | -2280.00 USD | -895.63% |
| 2014 | -229.00 USD | 80.79% |
| 2013 | -1192.00 USD | 93.11% |
| 2012 | -17.29 Thousand USD | 1.02% |
| 2011 | -17.47 Thousand USD | 3.56% |
| 2010 | -18.12 Thousand USD | -69.44% |
| 2009 | -10.69 Thousand USD | -238.34% |
| 2008 | -3161.00 USD | 70.32% |
| 2007 | -10.65 Thousand USD | 40.16% |
| 2006 | -17.79 Thousand USD | -4.79% |
| 2005 | -16.98 Thousand USD | 10.43% |
| 2004 | -18.96 Thousand USD | -884.53% |
| 2003 | -1926.00 USD | 91.47% |
| 2002 | -22.58 Thousand USD | -248.16% |
| 2001 | -6487.00 USD | -319.45% |
| 2000 | 2956.00 USD | -94.11% |
| 1999 | 50.22 Thousand USD | -83.76% |
| 1998 | 309.31 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -1310.00 USD | -43.48% |
| 2024 FY | -1310.00 USD | -40.26% |
| 2024 Q2 | -1397.00 USD | -843.92% |
| 2024 Q1 | -148.00 USD | 84.15% |
| 2024 Q3 | -913.00 USD | 34.65% |
| 2023 Q3 | -1692.00 USD | -33.65% |
| 2023 FY | -934.00 USD | 72.38% |
| 2023 Q4 | -934.00 USD | 44.8% |
| 2023 Q1 | -4766.00 USD | -40.92% |
| 2023 Q2 | -1266.00 USD | 73.44% |
| 2022 Q3 | -5765.00 USD | -537.72% |
| 2022 Q4 | -3382.00 USD | 41.34% |
| 2022 Q1 | -594.00 USD | -858.06% |
| 2022 Q2 | -904.00 USD | -52.19% |
| 2022 FY | -3382.00 USD | -5354.84% |
| 2021 Q2 | -1711.00 USD | -949.69% |
| 2021 FY | -62.00 USD | 61.96% |
| 2021 Q3 | -1069.00 USD | 37.52% |
| 2021 Q1 | -163.00 USD | 0.0% |
| 2021 Q4 | -62.00 USD | 94.2% |
| 2020 Q3 | -221.00 USD | 80.05% |
| 2020 FY | -163.00 USD | 76.98% |
| 2020 Q1 | -3110.00 USD | -339.27% |
| 2020 Q2 | -1108.00 USD | 64.37% |
| 2020 Q4 | -163.00 USD | 26.24% |
| 2019 Q3 | -486.00 USD | -18.83% |
| 2019 Q2 | -409.00 USD | -98.54% |
| 2019 Q1 | -206.00 USD | 59.29% |
| 2019 Q4 | -708.00 USD | -45.68% |
| 2019 FY | -708.00 USD | -39.92% |
| 2018 Q4 | -506.00 USD | 85.3% |
| 2018 FY | -506.00 USD | 30.78% |
| 2018 Q1 | -382.00 USD | 47.74% |
| 2018 Q2 | -504.00 USD | -31.94% |
| 2018 Q3 | -3442.00 USD | -582.94% |
| 2017 Q3 | -882.00 USD | -108.02% |
| 2017 FY | -731.00 USD | 77.87% |
| 2017 Q4 | -731.00 USD | 17.12% |
| 2017 Q2 | -424.00 USD | 50.64% |
| 2017 Q1 | -859.00 USD | 73.99% |
| 2016 Q1 | -480.00 USD | 78.95% |
| 2016 Q2 | -502.00 USD | -4.58% |
| 2016 Q3 | -590.00 USD | -17.53% |
| 2016 Q4 | -3303.00 USD | -459.83% |
| 2016 FY | -3303.00 USD | -44.87% |
| 2015 Q2 | -5809.00 USD | -208.33% |
| 2015 Q1 | -1884.00 USD | -722.71% |
| 2015 FY | -2280.00 USD | -895.63% |
| 2015 Q3 | -1996.00 USD | 65.64% |
| 2015 Q4 | -2280.00 USD | -14.23% |
| 2014 Q2 | -846.00 USD | 33.91% |
| 2014 Q3 | -84.00 USD | 90.07% |
| 2014 Q1 | -1280.00 USD | -7.38% |
| 2014 Q4 | -229.00 USD | -172.62% |
| 2014 FY | -229.00 USD | 80.79% |
| 2013 FY | -1192.00 USD | 93.11% |
| 2013 Q4 | -1192.00 USD | 54.78% |
| 2013 Q2 | -14.12 Thousand USD | 5.5% |
| 2013 Q1 | -14.94 Thousand USD | 13.57% |
| 2013 Q3 | -2636.00 USD | 81.34% |
| 2012 FY | -17.29 Thousand USD | 1.02% |
| 2012 Q4 | -17.29 Thousand USD | -7.21% |
| 2012 Q3 | -16.13 Thousand USD | 28.21% |
| 2012 Q2 | -22.47 Thousand USD | -40.24% |
| 2012 Q1 | -16.02 Thousand USD | 8.3% |
| 2011 FY | -17.47 Thousand USD | 3.56% |
| 2011 Q4 | -17.47 Thousand USD | -2.18% |
| 2011 Q3 | -17.1 Thousand USD | -3.93% |
| 2011 Q2 | -16.45 Thousand USD | 18.9% |
| 2011 Q1 | -20.29 Thousand USD | -11.97% |
| 2010 Q3 | -14.83 Thousand USD | -9.91% |
| 2010 Q1 | -15.58 Thousand USD | -45.75% |
| 2010 Q2 | -13.49 Thousand USD | 13.42% |
| 2010 Q4 | -18.12 Thousand USD | -22.17% |
| 2010 FY | -18.12 Thousand USD | -69.44% |
| 2009 Q2 | -12.33 Thousand USD | -177.03% |
| 2009 Q3 | -8629.00 USD | 30.07% |
| 2009 Q4 | -10.69 Thousand USD | -23.94% |
| 2009 FY | -10.69 Thousand USD | -238.34% |
| 2009 Q1 | -4454.00 USD | -40.9% |
| 2008 Q3 | -1394.00 USD | 70.89% |
| 2008 Q4 | -3161.00 USD | -126.76% |
| 2008 Q1 | -22.34 Thousand USD | -109.82% |
| 2008 Q2 | -4788.00 USD | 78.57% |
| 2008 FY | -3161.00 USD | 70.32% |
| 2007 FY | -10.65 Thousand USD | 40.16% |
| 2007 Q4 | -10.65 Thousand USD | 36.87% |
| 2007 Q3 | -16.87 Thousand USD | -4.5% |
| 2007 Q2 | -16.14 Thousand USD | 4.87% |
| 2007 Q1 | -16.96 Thousand USD | 4.65% |
| 2006 Q1 | -13.72 Thousand USD | 19.21% |
| 2006 FY | -17.79 Thousand USD | -4.79% |
| 2006 Q4 | -17.79 Thousand USD | -62.87% |
| 2006 Q3 | -10.92 Thousand USD | -3.42% |
| 2006 Q2 | -10.56 Thousand USD | 23.0% |
| 2005 Q4 | -16.98 Thousand USD | 38.01% |
| 2005 Q2 | -25.36 Thousand USD | -62.08% |
| 2005 Q1 | -15.64 Thousand USD | 17.48% |
| 2005 Q3 | -27.39 Thousand USD | -8.03% |
| 2005 FY | -16.98 Thousand USD | 10.43% |
| 2004 Q3 | -11.27 Thousand USD | 51.33% |
| 2004 Q2 | -23.17 Thousand USD | 6.98% |
| 2004 Q4 | -18.96 Thousand USD | -68.13% |
| 2004 FY | -18.96 Thousand USD | -884.53% |
| 2004 Q1 | -24.91 Thousand USD | -1193.46% |
| 2003 FY | -1926.00 USD | 91.47% |
| 2003 Q3 | -18.85 Thousand USD | -122.1% |
| 2003 Q4 | -1926.00 USD | 89.78% |
| 2003 Q2 | -8487.00 USD | -106.55% |
| 2003 Q1 | -4109.00 USD | 81.81% |
| 2002 FY | -22.58 Thousand USD | -248.16% |
| 2002 Q3 | -3958.00 USD | 70.57% |
| 2002 Q1 | -12.41 Thousand USD | -91.34% |
| 2002 Q2 | -13.45 Thousand USD | -8.36% |
| 2002 Q4 | -22.58 Thousand USD | -470.62% |
| 2001 Q2 | -719.00 USD | -124.05% |
| 2001 Q4 | -6487.00 USD | 77.36% |
| 2001 FY | -6487.00 USD | -319.45% |
| 2001 Q1 | 2989.00 USD | 1.12% |
| 2001 Q3 | -28.65 Thousand USD | -3885.95% |
| 2000 FY | 2956.00 USD | -94.11% |
| 2000 Q4 | 2956.00 USD | 0.0% |
| 1999 FY | 50.22 Thousand USD | -83.76% |
| 1998 FY | 309.31 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.023% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.003% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 99.475% |
| Rebus Holdings, Inc. | 305 Thousand USD | 100.43% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 99.979% |
| Qrons Inc. | 351.42 Thousand USD | 100.373% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 100.21% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.003% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 93.581% |
| Skye Bioscience, Inc. | -5.72 Million USD | 99.977% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.008% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.032% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.326% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.996% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.058% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.141% |
| Mesoblast Limited | 55.85 Million USD | 100.002% |
| Marizyme, Inc. | 18.56 Million USD | 100.007% |
| Genus plc | 190.6 Million USD | 100.001% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.059% |
| Pharming Group N.V. | 109.8 Million USD | 100.001% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.152% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.108% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 100.193% |
| ContraFect Corporation | -6.02 Million USD | 99.978% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 100.973% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.113% |
| IMV Inc. | 7.67 Million USD | 100.017% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.024% |
| MultiCell Technologies, Inc. | 90.04 USD | 1554.909% |
| ONE Bio Corp. | 9.04 Million USD | 100.014% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 99.822% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.01% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 100.096% |
| Q BioMed Inc. | 4.06 Million USD | 100.032% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.004% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.13% |
| Biomind Labs Inc. | 711.4 Thousand USD | 100.184% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.002% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.066% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.01% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.364% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 100.937% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 106.594% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.059% |
| GB Sciences, Inc. | 1.74 Million USD | 100.075% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 99.287% |
| HST Global, Inc. | 96.79 Thousand USD | 101.353% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 100.635% |
| Halberd Corporation | 144.72 Thousand USD | 100.905% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.133% |
| Agentix Corp. | 37.63 Thousand USD | 103.481% |
| Resverlogix Corp. | 6.45 Million USD | 100.02% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 99.805% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.997% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.019% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.048% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 99.985% |
| AVAX Technologies, Inc. | -5.9 Million USD | 99.978% |
| Zenith Capital Corp. | 10.06 Thousand USD | 113.017% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 100.654% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.055% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 100.796% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 92.849% |
| Kadimastem Ltd | -253.1 Thousand USD | 99.482% |
| Helix BioMedix, Inc. | -2.57 Million USD | 99.949% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.006% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.029% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 100.651% |
| LadRx Corporation | -2.03 Million USD | 99.936% |
| Cell Source, Inc. | 9.23 Million USD | 100.014% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.206% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.206% |
| NovAccess Global Inc. | 2.17 Million USD | 100.06% |
| Affymax, Inc. | -5.59 Million USD | 99.977% |
| Itoco Inc. | 228.3 Thousand USD | 100.574% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 100.963% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.026% |
| Mobile Lads Corp. | 484.23 Thousand USD | 100.271% |
| CytoDyn Inc. | 20.26 Million USD | 100.006% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -102.473% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 85.866% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.017% |
| SYBLEU INC | 473.71 Thousand USD | 100.277% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.029% |
| International Stem Cell Corporation | 2.59 Million USD | 100.051% |
| Bioxytran, Inc. | 1.89 Million USD | 100.069% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 102.099% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.06% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 100.038% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.015% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 100.17% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 99.895% |
| Neutra Corp. | 52.18 Thousand USD | 102.51% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 99.947% |
| PureTech Health plc | -167.19 Million USD | 99.999% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 99.465% |
| IXICO plc | -4.44 Million USD | 99.971% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.01% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.002% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 99.997% |